For Immediate Release
Chicago, IL – August 28, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include GlaxoSmithKline (
GSK
- Analyst Report
)
, Theravance, Inc. (
THRX
- Analyst Report
)
, Pfizer (
PFE
- Analyst Report
)
, BP Plc (
BP
- Analyst Report
)
and Talisman Energy (
TLM
- Analyst Report
)
.
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Pipeline Advances at Glaxo/Theravance
GlaxoSmithKline (
GSK
- Analyst Report
)
andTheravance, Inc. (
THRX
- Analyst Report
)
recently announced that they have completed the phase III program for their pipeline candidate, LAMA/LABA (UMEC/VI), for chronic obstructive pulmonary disease (COPD). LAMA/LABA is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).
The 52-week safety study and two replicate 12-week crossover exercise studies for LAMA/LABA are now complete. Data from these studies will be presented at upcoming scientific meetings. Glaxo remains on track to submit regulatory applications for LAMA/LABA toward the end of 2012.
Earlier, in July 2012, Glaxo and Theravance had announced data from four pivotal phase III studies of LAMA/LABA. While two studies compared the efficacy and safety of LAMA/LABA with VI, UMEC and placebo, the two other studies compared the efficacy and safety of LAMA/LABA withPfizer’s (
PFE
- Analyst Report
)
Spiriva. The four studies together enrolled over 4,000 COPD patients.
In both the placebo-controlled, 24-week, randomized, double-blind studies, LAMA/LABA showed a statistically significant benefit over VI, UMEC and placebo. In the first head-to-head comparison with Spiriva, LAMA/LABA showed a statistically significant improvement. However, in the second study, LAMA/LABA failed to do so although it demonstrated numerical difference.
Our Take
LAMA/LABA, if approved, will be positioned as a replacement for Advair, one of Glaxo’s highest revenue earners with 2011 sales exceeding £5 billion. We note that Glaxo along with Theravance is also developing other COPD candidates including Breo (proposed brand name Relvar in the EU, formerly known as Relovair) and MABA (GSK961081).
Glaxo, in May 2012, had acquired 10,000,000 shares of Theravance for approximately $21.2887 per share. With this transaction, Glaxo increased its holding in Theravance to 26.7% from 18.3%. The increased holding by Glaxo reflects its confidence in the pipeline candidates.
We currently have a Neutral recommendation on Theravance, which carries a Zacks #3 Rank (short-term Hold rating). We, however, have an Underperform recommendation on Glaxo, which carries a Zacks #4 Rank (short-term Sell rating). Glaxo’s second quarter results missed expectations. The company is facing headwinds like generic competition and EU pricing pressure.
Cost Overruns Dog BP Project
BP Plc (
BP
- Analyst Report
)
has incurred a huge cost overrun on its Skarv project off Norway, which got deferred mainly due to supply hindrances to obtain some vital equipment and services. The company is now trying hard to start operations in the field by the end of 2012.
The overrun cost is estimated at over NOK 10 billion ($1.7 billion) on the original budget of NOK 34 billion. The project is under pressure due to the elevated expenses associated with production setback, fixing of vessel charters, engineering services and an extended yard stay for the floater.
The repetitive weather-related problems such as high waves have prohibited the set up of risers and thus postponed the commissioning of the field’s floating production, storage and offloading (FPSO) vessel by over a year to December 2012. The field’s FPSO would be the largest in operation in the Norwegian region.
Earlier, the project was delayed due to complex and prolonged repair work that had to be performed on the turret, assembled at South Korea’s Samsung Heavy Industries and supplied by the Dutch contractor SBM Offshore.
Initially, BP had given the contract to Bluewater, but later cancelled it as Samsung did not possess the capacity to honor the order. SBM was finally contracted for engineering of the turret. SBM has also been criticized over its supply of offshore production unit forTalisman Energy’s (
TLM
- Analyst Report
)
disturbed Yme project off Norway.
However, BP management has defended SBM and said that the Skarv development is now moving as scheduled and will start producing in December, as the last of the field’s 13 risers was installed in the turret this summer.
The Skarv field is estimated to hold oil and condensate reserves of around 104 million barrels and gas reserves of about 42.1 billion cubic meters of gas. Initially, BP targets a daily yield rate of 80,000 barrels from the field.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – August 28, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include GlaxoSmithKline ( GSK - Analyst Report ) , Theravance, Inc. ( THRX - Analyst Report ) , Pfizer ( PFE - Analyst Report ) , BP Plc ( BP - Analyst Report ) and Talisman Energy ( TLM - Analyst Report ) .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Pipeline Advances at Glaxo/Theravance
GlaxoSmithKline ( GSK - Analyst Report ) andTheravance, Inc. ( THRX - Analyst Report ) recently announced that they have completed the phase III program for their pipeline candidate, LAMA/LABA (UMEC/VI), for chronic obstructive pulmonary disease (COPD). LAMA/LABA is a combination of a long-acting muscarinic antagonist/LAMA (GSK573719 or umeclidinium bromide/UMEC) and a long-acting beta2 agonist/LABA (vilanterol/VI).
The 52-week safety study and two replicate 12-week crossover exercise studies for LAMA/LABA are now complete. Data from these studies will be presented at upcoming scientific meetings. Glaxo remains on track to submit regulatory applications for LAMA/LABA toward the end of 2012.
Earlier, in July 2012, Glaxo and Theravance had announced data from four pivotal phase III studies of LAMA/LABA. While two studies compared the efficacy and safety of LAMA/LABA with VI, UMEC and placebo, the two other studies compared the efficacy and safety of LAMA/LABA withPfizer’s ( PFE - Analyst Report ) Spiriva. The four studies together enrolled over 4,000 COPD patients.
In both the placebo-controlled, 24-week, randomized, double-blind studies, LAMA/LABA showed a statistically significant benefit over VI, UMEC and placebo. In the first head-to-head comparison with Spiriva, LAMA/LABA showed a statistically significant improvement. However, in the second study, LAMA/LABA failed to do so although it demonstrated numerical difference.
Our Take
LAMA/LABA, if approved, will be positioned as a replacement for Advair, one of Glaxo’s highest revenue earners with 2011 sales exceeding £5 billion. We note that Glaxo along with Theravance is also developing other COPD candidates including Breo (proposed brand name Relvar in the EU, formerly known as Relovair) and MABA (GSK961081).
Glaxo, in May 2012, had acquired 10,000,000 shares of Theravance for approximately $21.2887 per share. With this transaction, Glaxo increased its holding in Theravance to 26.7% from 18.3%. The increased holding by Glaxo reflects its confidence in the pipeline candidates.
We currently have a Neutral recommendation on Theravance, which carries a Zacks #3 Rank (short-term Hold rating). We, however, have an Underperform recommendation on Glaxo, which carries a Zacks #4 Rank (short-term Sell rating). Glaxo’s second quarter results missed expectations. The company is facing headwinds like generic competition and EU pricing pressure.
Cost Overruns Dog BP Project
BP Plc ( BP - Analyst Report ) has incurred a huge cost overrun on its Skarv project off Norway, which got deferred mainly due to supply hindrances to obtain some vital equipment and services. The company is now trying hard to start operations in the field by the end of 2012.
The overrun cost is estimated at over NOK 10 billion ($1.7 billion) on the original budget of NOK 34 billion. The project is under pressure due to the elevated expenses associated with production setback, fixing of vessel charters, engineering services and an extended yard stay for the floater.
The repetitive weather-related problems such as high waves have prohibited the set up of risers and thus postponed the commissioning of the field’s floating production, storage and offloading (FPSO) vessel by over a year to December 2012. The field’s FPSO would be the largest in operation in the Norwegian region.
Earlier, the project was delayed due to complex and prolonged repair work that had to be performed on the turret, assembled at South Korea’s Samsung Heavy Industries and supplied by the Dutch contractor SBM Offshore.
Initially, BP had given the contract to Bluewater, but later cancelled it as Samsung did not possess the capacity to honor the order. SBM was finally contracted for engineering of the turret. SBM has also been criticized over its supply of offshore production unit forTalisman Energy’s ( TLM - Analyst Report ) disturbed Yme project off Norway.
However, BP management has defended SBM and said that the Skarv development is now moving as scheduled and will start producing in December, as the last of the field’s 13 risers was installed in the turret this summer.
The Skarv field is estimated to hold oil and condensate reserves of around 104 million barrels and gas reserves of about 42.1 billion cubic meters of gas. Initially, BP targets a daily yield rate of 80,000 barrels from the field.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Read the full reports :
Analyst Report on GSK
Analyst Report on THRX
Analyst Report on PFE
Analyst Report on BP
Analyst Report on TLM